# TCG Crossover Management

TCG Crossover Management is a Private Equity based in Palo Alto, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Palo Alto, United States
- **Region:** North America
- **Address:** Palo Alto, CA, United States
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** tcgcrossover.com
- **LinkedIn:** https://www.linkedin.com/company/tcg-crossover

## Regulatory record

- **CRD number:** 311718
- **SEC file number:** 801-120001
- **Registration status:** APPROVED
- **Latest Form ADV filing:** 2026-03-31T05:00:00.000Z
- **Reports private funds:** Yes
- **Private funds reported:** 0
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/311718

## About

TCG Crossover (TCGX) is a science-driven investment firm dedicated to advancing disruptive medicines. It is an investment firm focused on innovative biotech companies, investing in visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines. With offices in Palo Alto, San Francisco, and New York City, it has supported companies in North America, Europe, and China. The firm invests out of closed-end funds and supports private and public companies building the future of medicine.

## Sectors

- Enterprise Software
- AI/ML
- Digital Health
- FinTech

## People

- Chen Yu — Managing Partner and founder
- Cariad Chester — Managing Partner
- Giuliano Marostica — Managing Partner
- Dandan Dong — Venture Partner
- George Feng — Associate (Bioengineer)
- Bill Zhang — Analyst
- Haithem Laaribi — Associate
- Suan Tuang — Associate
- Michael Albert — Associate
- Craig Skaling — COO & CFO
- Brad Balter — Head of Trading
- Ed Amorosi — Head of Capital Formation & Investor Relations
- Jing Wu — Controller
- Echo Qin — Senior Accounting Manager
- Kate Garcia — Operations
- Robert Tjian — PhD, Science Partner
- Roger Perlmutter — MD, Science Partner
- Charles Sawyers — MD, Science Partner
- Richard Scheller — PhD, Science Partner
- Vishva M. Dixit — MD, Science Partner
- Huda Y. Zoghbi — MD, Science Partner
- Charles Zuker — PhD, Science Partner
- Helen Hobbs — PhD, Science Partner

## Questions

### How does TCG Crossover's crossover mandate actually work in practice?

The firm invests across a company's transition from late-stage private funding rounds through IPO and into the public aftermarket. This means writing equity checks in pre-IPO crossover rounds, participating in the IPO allocation, and managing post-IPO positions rather than distributing or selling at the lockup expiry. The mandate concentrates on 10 to 14 core positions.

### Does TCG Crossover participate in fund commitments or only direct deals?

The firm focuses on direct equity investments — both private placement rounds in late-stage companies and public-market equity positions in newly listed issuers. There is no public record of TCG Crossover allocating capital to third-party venture funds as a limited partner.

## Related profiles

- [TCG Asset Management](https://altss.com/profile/tcg-asset-management)
- [Tcha Partners](https://altss.com/profile/tcha-partners)

---

Last updated: 2026-08-11T15:08:18.003Z

Canonical page: https://altss.com/profile/tcg-crossover-management

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology